Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5365_Библиотеки_им_академика_М_И_Перельмана
.pdf
94
https://t.me/medicina_free
Biomarkers as Targeted Herbal Drug Discovery
Agarwal, S. M., Raghav, D., Singh, H., et al., (2011). CCDB: A curated database of genes
involved in cervix cancer. Nucleic Acids Res., 39(Database), D975–D979.
Agnihotri, S. M., & Vavia, P. R., (2009). Diclofenac-loaded biopolymeric nanosuspensions
for ophthalmic application. Nanomedicine, 5(1), 90–95.
Alvarado, H. L., Abrego, G., Souto, E. B., et al., (2015). Nanoemulsions for dermal controlled
release of oleanolic and ursolic acids: In vitro, ex vivo, and in vivo characterization. Colloids
Surf. B. Biointerfaces., 130, 40–47.
Amiji, M. M., (2006). Nanotechnology for Cancer Therapy. CRC Press, USA.
Araújo, J., Gonzalez, E., Egea, M. A., et al., (2009). Nanomedicines for ocular NSAIDs:
Safety on drug delivery. Nanomedicine, 5(4), 394–401.
Araujo, J., Vega, E., Lopes, C., et al., (2009). Effect of polymer viscosity on physicochemical
properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B
Biointerfaces, 72, 48–56.
Baek, J. H., Lee, Y. S., Kang, C. M., et al., (1997). Intracellular Ca
acid-induced apoptosis in human leukemic HL-60 cells. Int. J. Cancer, 73(5), 725–728.
Bari, A., Bloise, N., Fiorilli, S., et al., (2017). Copper-containing mesoporous bioactive glass
nanoparticles as multifunctional agent for bone regeneration. Acta Biomater., 55, 493–504.
Bast, Jr. R. C., Hennessy, B., & Mills, G. B., (2009). The biology of ovarian cancer: New
opportunities for translation. Nat Rev Cancer, 9(6), 415–428.
Bertrand, N., Wu, J., Xu, X., et al., (2014). Cancer nanotechnology: The impact of passive and
active targeting in the era of modern cancer biology. Adv. Drug Del. Rev., 66, 2–25.
Both, D. M., Goodtzova, K., Yarosh, D. B., et al., (2002). Liposome-encapsulated ursolic
acid increases ceramides and collagen in human skin cells. Arch. Dermatol. Res., 293(11),
569–575.
Caldeira, D. A. L., S., Vinícius, M. N. M., Salviano, T. C., et al., (2013). Preparation,
physicochemical characterization, and cell viability evaluation of long-circulating and
pH-sensitive liposomes containing ursolic acid. BioMed. Res. Int., 467147.
Cerga, O., Borcan, F., Ambrus, R., et al., (2011). Syntheses of new cyclodextrin complexes
with oleanolic and ursolic acids. J. Agroaliment. Process. Technol., 17, 405–409.
Cha, H. J., Park, M. T., Chung, H. Y., et al., (1998). Ursolic acid-induced down-regulation of
MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in
HT1080 human fibro sarcoma cells. Oncogene., 16(6), 771–778.
Chen, Q., Luo, S., Zhang, Y., et al., (2011). Development of a liquid chromatography-mass
spectrometry method for the determination of ursolic acid in rat plasma and tissue:
Application to the pharmacokinetic and tissue distribution study. Anal. Bioanal. Chem.,
399(8), 2877–2884.
Chen, Y. J., Pao, J. L., Chen, C. S., et al., (2017). Evaluation of new biphasic calcium
phosphate bone substitute: Rabbit femur defect model and preliminary clinical results. J.
Med. Biol. Eng., 37(1), 85–93.
Chen, Y., Kawazoe, N., & Chen, G., (2018). Preparation of dexamethasone-loaded biphasic
calcium phosphate nanoparticles/collagen porous composite scaffolds for bone tissue
engineering. Acta Biomater., 67, 341–353.
Choi, Y. H., Baek, J. H., Yoo, M. A., et al., (2000). Induction of apoptosis by ursolic acid
through activation of caspases and down-regulation of c-IAPs in human prostate epithelial
cells. Int. J. Oncol., 17(3), 565–571.
2+
release mediates ursolic
95 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
Duan, X., Liao, H. X., Zou, H. Z., et al., (2017). An injectable, biodegradable calcium phosphate
cement containing poly lactic-co-glycolic acid as a bone substitute in ex vivo human vertebral
compression fracture and rabbit bone defect models. Connect Tissue Res., 59(1), 55–65.
Gao, N., Cheng, S., Budhraja, A., et al., (2012). Ursolic acid induces apoptosis in human
leukemia cells and exhibits anti-leukemic activity in nude mice through the PKB pathway.
Br. J. Pharmacol., 165(6), 1813–1826.
Gao, Y., Li, Z., Xie, X., et al., (2015). Dendrimeric anticancer prodrugs for targeted delivery of
ursolic acid to folate receptor expressing cancer cells: Synthesis and biological evaluation.
Eur. J. Pharm. Sci., 70, 55–63.
Gao, Y., Xie, J., Chen, H., et al., (2014). Nanotechnology-based intelligent drug design for
cancer metastasis treatment. Biotechnol. Adv., 32(4), 761–777.
Gong, Y. Y., Liu, Y. Y., Yu, S., et al., (2014). Ursolic acid suppresses growth and
adrenocorticotrophic hormone secretion in AtT20 cells as a potential agent targeting
adrenocorticotrophic hormone-producing pituitary adenoma. Mol. Med. Rep., 9(6),
2533–2539.
Gonzalez-Mira, E., Egea, M. A., Souto, E. B., et al., (2011). Optimizing flurbiprofen-loaded NLC
by central composite factorial design for ocular delivery. Nanotechnology, 22(4), 045101.
Gunther, G., Berrios, E., Pizarro, N., et al., (2015). Flavonoids in micro heterogeneous media,
relationship between their relative location and their reactivity towards singlet oxygen.
PLoS One, 10(6), e0129749.
Gupta, H., Aqil, M., Khar, R. K., et al., (2010). Sparfloxacin-loaded PLGA nanoparticles for
sustained ocular drug delivery. Nanomedicine, 6(2), 324–333.
Han, S. K., Ko, Y. I., Park, S. J., et al., (1997). Oleanolic acid and ursolic acid stabilize
liposomal membranes. Lipids, 32(7), 769–773.
Harmand, P. O., Duval, R., Delage, C., et al., (2005). Ursolic acid induces apoptosis through
mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells. Int. J.
Cancer, 114(1), 1–11.
Hench, L. L., (2006). The story of bioglass. J. Mater. Sci. Mater. Med., 17(11), 967–978.
Hirsh, S., Huber, L., Zhang, P., et al., (2014). A single ascending dose, initial clinical
pharmacokinetic and safety study of ursolic acid in healthy adult volunteers. FASEB J.,
28(1), 1044.
Holden, C. A., Tyagi, P., Thakur, A., et al., (2012). Polyamidoamine dendrimer hydrogel for
enhanced delivery of antiglaucoma drugs. Nanomedicine, 8(5), 776–783.
Hollosy, F., Meszaros, G., Bokonyi, G., et al., (2000). Cytostatic, cytotoxic and protein
tyrosine kinase inhibitory activity of ursolic acid in A431 human tumor cells. Anticancer
Res., 20(6B), 4563–4570.
Hsu, H. Y., Yang, J. J., & Lin, C. C., (1997). Effects of oleanolic acid and ursolic acid on
inhibiting tumor growth and enhancing the recovery of hematopoietic system post
irradiation in mice. Cancer Lett., 111(1, 2), 7–13.
Huang, C. Y., Lin, C. Y., Tsai, C. W., et al., (2011). Inhibition of cell proliferation, invasion,
and migration by ursolic acid in human lung cancer cell lines. Toxicol. In Vitro, 25(7),
1274–1280.
Jäger, S., Laszczyk, M. N., & Scheffler, A., (2008). A preliminary pharmacokinetic study of
betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba
cortex). Molecules, 13(12), 3224–3235.
96
https://t.me/medicina_free
Biomarkers as Targeted Herbal Drug Discovery
Jäger, S., Trojan, H., Kopp, T., et al., (2009). Pentacyclic triterpene distribution in various
plants-rich sources for a new group of multi-potent plant extracts. Molecules, 14(6),
2016–2031.
Jamal, M., Imam, S. S., Aqil, M., et al., (2015). Transdermal potential and anti-arthritic efficacy
of ursolic acid from niosomal gel systems. Int. Immunopharmacol., 29(2), 361–369.
Jeong, D. W., Kim, Y. H., Kim, H. H., et al., (2007). Dose-linear pharmacokinetics of
oleanolic acid after intravenous and oral administration in rats. Biopharm. Drug Dispos,
28(2), 51–57.
Kang, M. S., Lee, N. H., Singh, R. K., et al., (2018). Nanocements produced from mesoporous
bioactive glass nanoparticles. Biomaterials, 162, 183–199.
Kanjoormana, M., & Kuttan, G., (2010). Antiangiogenic activity of ursolic acid. Integr.
Cancer Ther., 9(2), 224–235.
Karalezli, A., Borazan, M., & Akova, Y. A., (2008). Intracameral triamcinolone acetonide to
control postoperative inflammation following cataract surgery with pharmacoemulsification.
Acta Ophthalmol., 86(2), 183–187.
Kassi, E., Sourlingas, T. G., Spiliotaki, M., et al., (2009). Ursolic acid triggers apoptosis and
Bcl-2 downregulation in MCF-7 breast cancer cells. Cancer Invest., 27(7), 723–733.
Kawase, R., Ishiwata, T., Matsuda, Y., et al., (2010). Expression of fibroblast growth factor
receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. Int.
J. Oncol., 36(2), 331–340.
Kim, D. K., Baek, J. H., Kang, C. M., et al., (2000). Apoptotic activity of ursolic acid may
correlate with the inhibition of initiation of DNA replication. Int. J. Cancer., 87(5), 629–636.
Kim, H. D., Amirthalingam, S., Kim, S. L., et al., (2017). Biomimetic materials and fabrication
approaches for bone tissue engineering. Adv. Healthc. Mater., 6(23), 1700612.
Kim, J. A., Lim, J., Naren, R., et al., (2016). Effect of the biodegradation rate controlled by
pore structures in magnesium phosphate ceramic scaffolds on bone tissue regeneration in
vivo. Acta Biomater., 44, 155–167.
Kim, K. H., Seo, H. S., Choi, H. S., et al., (2011). Induction of apoptotic cell death by
ursolic acid through mitochondrial death pathway and extrinsic death receptor pathway in
MDA-MB-231 cells. Arch. Pharmacal. Res., 34(8), 1363–1372.
Kwon, T., Lee, B., Chung, S. H., et al., (2009). Bull, synthesis and NO production
inhibitory activities of ursolic acid and oleanolic acid derivatives. Korean Chem Soc.,
30(1), 119–123.
Li, C., Zhang, J., ZU, Y. J., et al., (2015). Biocompatible and biodegradable nanoparticles
for enhancement of anti-cancer activities of phytochemicals. Chin. J. Nat. Med., 13(9),
641–652.
Li, Z., Jiang, H., Xu, C. M., et al., (2015). A review: Using nanoparticles to enhance absorption
and bioavailability of phenolic phytochemicals. Food Hydrocolloid, 43, 153–164.
Liao, Q., Yang, W., Jia, Y., et al., (2005). LC-MS determination and pharmacokinetic studies
of ursolic acid in rat plasma after administration of the traditional Chinese medicinal
preparation Lu-Ying extract. YakugakuZasshi, 125(6), 509–515.
Lide, D. R., (2007). CRC Handbook of Chemistry and Physics 88
TH
Edition 2007–2008 (pp.
3–516). CRC Press, Taylor & Francis, Boca Raton, F L.
Limami, Y., Pinon, A., Leger, D. Y., et al., (2011). HT-29 colorectal cancer cells undergoing
apoptosis overexpress COX-2 to delay ursolic acid-induced cell death. Biochimie., 93(4),
749–757.
97 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
Limami, Y., Pinon, A., Leger, D. Y., et al., (2012). The P2Y 2/Src/p38/COX-2 pathway is
involved in the resistance to ursolic acid-induced apoptosis in colorectal and prostate cancer
cells. Biochimie., 94(8), 1754–1763.
Lin, D., Chai, Y., Ma, Y., et al., (2017). Rapid initiation of guided bone regeneration driven
by spatiotemporal delivery of IL-8 and BMP-2 from hierarchical MBG-based scaffold.
Biomaterials, 196, 122–137.
Lin, D., Zhang, R., Feng, T., et al., (2014). Ursolic acid induces U937 cells differentiation by
PI3K/Akt pathway activation. Chin. J. Nat. Med., 12(1), 15–19.
Liu, J., (1995). Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol., 49(2),
57–68.
Logith, K. R., Keshav, N. A., Dhivya, S., et al., (2016). A review of chitosan and its derivatives
in bone tissue engineering, Carbohyd. Polym., 151, 172–188.
Mandelli, A. M., Nadia, A., Denise, C. J., et al., (2013). Evaluation of physical and chemical
stability of nanostructured lipid carries containing ursolic acid in cosmetic formulation. J.
Appl. Pharm. Sci., 3(1), 5–8.
Merisko-Liversidge, E., Liversidge, G. G., & Cooper, E. R., (2003). Nanosizing: A formulation
approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci., 18(2), 113–120.
Messner, B., Zeller, I., Ploner, C., et al., (2011). Ursolic acid causes DNA-damage,
p53-mediated, mitochondria-and caspase-dependent human endothelial cell apoptosis,
and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis, 219(2),
402–408.
Moghaddam, S. P. H., Yazdimamaghani, M., & Ghandehari, H., (2018). Glutathione-sensitive
hollow mesoporous silica nanoparticles for controlled drug delivery. J Control Release,
282, 62–75.
Morales, J. O., Valdes, K., Morales, J., et al., (2015). Lipid nanoparticles for the topical
delivery of retinoids and derivatives. Nanomedicine, 10(2), 253–269.
Nabiyouni, M., Bruckner, T., Zhou, H., et al., (2018). Magnesium-based bioceramics in
orthopedic applications. Acta Biomater., 66, 23–43.
Nagarwal, R. C., Kant, S., Singh, P. N., et al., (2009). Polymeric nanoparticulate system: A
potential approach for ocular drug delivery. J Control Release, 136(1), 2–13.
Nam, H., & Kim, M. M., (2013). Ursolic acid induces apoptosis of SW480 cells via p53
activation. Food Chem. Toxicol., 62, 579–583.
Novotny, L., Vachalkova, A., & Biggs, D., (2001). Ursolic acid: An anti-tumorigenic and
chemo preventive activity: Mini review. Neoplasma., 48(4), 241–246.
O’Neil, M. J., (2006). The Merck Index: An Encyclopedia of Chemicals, Drugs, and
Biologicals (p. 1699). Whitehouse Station, NJ: Merck and Co., Inc.
Ovesna, Z., Vachalkova, A., Horvathova, K., et al., (2004). Pentacyclic triterpenoic acids:
New chemo protective compounds: Mini review. Neoplasma., 51(5), 327–333.
Park, J. H., Kwon, H. Y., Sohn, E. J., et al., (2013). Inhibition of Wnt/β-catenin signaling
mediates ursolic acid-induced apoptosis in PC-3 prostate cancer cells. Pharmacol. Rep.,
65(5), 1366–1374.
Park, S. S., & Ha, C. S., (2018). Hollow mesoporous functional hybrid materials: Fascinating
platforms for advanced applications. Adv. Funct. Mater., 28, 1703814.
Parkin, D. M., Bray, F., Ferlay, J., et al., (2001). Estimating the world cancer burden: Globocan
2000. Int.J. Cancer, 94(2), 153–156.
98
https://t.me/medicina_free
Pathak, A. K., Bhutani, M., Nair, A. S., et al., (2007). Ursolic acid inhibits STAT3 activation
pathway leading to suppression of proliferation and chemo sensitization of human multiple
myeloma cells. Mol. Cancer Res., 5(9), 943–955.
Pattni, B. S., Chupin, V. V., & Torchilin, V. P., (2015). New developments in liposomal drug
delivery. Chem. Rev., 115(19), 10938–10966.
Phongsavan, K., Phengsavanh, A., Wahlström, R., et al., (2010). Women’s perception of
cervical cancer and its prevention in rural Laos. Int. J. Gynecol Cancer, 20(5), 821–826.
Qian, Z., Wang, X., Song, Z., et al., (2015). A Phase I trial to evaluate the multiple-dose safety
and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors.
BioMed. Res. Int., 809714.
Rezwan, K., Chen, Q. Z., Blaker, J. J., et al., (2006). Biodegradable and bioactive porous
polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials, 27(18),
3413–3431.
Sandoval, C., Ortega, A., Sanchez, S. A., et al., (2015). Structuration in the interface of direct
and reversed micelles of sucrose esters, studied by fluorescent techniques. PLoS One.,
10(4), e0123669.
Saraswati, S., Agrawal, S. S., & Alhaider, A. A., (2013). Ursolic acid inhibits tumor
angiogenesis and induces apoptosis through mitochondrial-dependent pathway in Ehrlich
as cites carcinoma tumor. Chem. Biol. Interact., 206(2), 153–165.
Shanmugam, M. K., Dai, X., Kumar, A. P., et al., (2013). Ursolic acid in cancer prevention and
treatment: Molecular targets, pharmacokinetics, and clinical studies. Biochem. Pharmacol.,
85(11), 1579–1587.
Shanmugam, M. K., Ong, T. H., Kumar, A. P., et al., (2012). Ursolic acid inhibits the initiation,
progression of prostate cancer and prolongs the survival of TRAMP mice by modulating
pro-inflammatory pathways. PLoS One, 7(3), e32476.
Shetty, P., Mangaonkar, K., Sane, R., et al., (2007). Pharmacokinetic analysis of ursolic acid
in Alstoniascholaris R. Br. by high-performance thin-layer chromatography. JPC J. Planar.
Chromatogr. Modern TLC, 20(2), 117–120.
Shin, S. W., & Park, J. W., (2013). Ursolic acid sensitizes prostate cancer cells to TRAIL-
mediated apoptosis. Biochim. Biophys. Acta, 1833(3), 723–730.
Shin, S. W., Kim, S. Y., & Park, J. W., (2012). Autophagy inhibition enhances ursolic acid-
induced apoptosis in PC3 cells. Biochim. Biophys. Acta, 1823(2), 451–457.
Shishodia, S., Majumdar, S., Banerjee, S., et al., (2003). Ursolic acid inhibits nuclear factor-
kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha
kinase and p65 phosphorylation: Correlation with down-regulation of cyclooxygenase 2,
matrix metalloproteinase 9, and cyclin D1. Cancer Res., 63(15), 4375–4383.
Siegel, R., Naishadham, D., & Jemal, A., (2013). Cancer statistics. CA Cancer J. Clin., 63(1),
11–30.
Singh, R., Bharti, N., Madan, J., et al., (2010). Characterization of cyclodextrin inclusion
complexes: A review. J. Pharm. Sci. Technol., 2(3), 171–183.
Soica, C., Oprean, C., Borcan, F., et al., (2014). The synergistic biologic activity of oleanolic and
ursolic acids in complex with hydroxypropyl-γ-cyclodextrin. Molecules, 19(4), 4924–4940.
Subbaramaiah, K., Michaluart, P., Sporn, M. B., et al., (2000). Ursolic acid inhibits
cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res., 60(9),
2399–2404.
Suh, N., Honda, T., Finlay, H. J., et al., (1998). Novel triterpenoids suppress inducible nitric
oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages.
Cancer Res., 58(4), 717–723.
Biomarkers as Targeted Herbal Drug Discovery
99 Ursolic Acid: A Pentacyclic Triterpene from Plants in Nanomedicine
https://t.me/medicina_free
Sultana, N., (2011). Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic
acid and related derivatives as medicinally important natural product. J. Enzyme Inhib.
Med. Chem., 26(5), 616–642.
Sun, Z., Ma, C. H., Yang, L., et al., (2011). Production of ursolic acid nanoparticles by
supercritical antisolvent precipitation. Adv. Mater. Res., 233–235, 2210–2214.
Tansik, G., Kilic, E., Beter, M., et al., (2016). A glycosaminoglycan mimetic peptide nanofiber
gel as an osteoinductive scaffold. Biomater. Sci., 4(9), 1328–1339.
Uchegbu, I. F., & Florence, A. T., (1995). Non-ionic surfactant vesicles (niosomes): Physical
and pharmaceutical chemistry. Adv. Colloid Interface Sci., 58(1), 1–55.
Valdes, K., Morilla, M. J., Romero, E., et al., (2014). Physicochemical characterization
and cytotoxic studies of nonionic surfactant vesicles using sucrose esters as oral delivery
systems. Colloid Surf. B Biointerfaces., 117, 1–6.
Vasconcelos, M. A., Royo, V. A., Ferreira, D. S., et al., (2006). In vivo analgesic and
anti-inflammatory activities of ursolic acid and oleanoic acid from Miconia albicans
(Melastomataceae). Z Naturforsch C, 61(7/8), 477–482.
Wang, J., Liu, L., Qiu, H., et al., (2013). Ursolic acid simultaneously targets multiple signaling
pathways to suppress proliferation and induce apoptosis in colon cancer cells. PLoS One,
8(5), e63872.
Wang, S., Su, R., Nie, S., et al., (2014). Application of nanotechnology in improving bioavailability
and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem., 25(4), 363–376.
Wang, X. H., Zhou, S. Y., Qian, Z. Z., et al., (2013). Evaluation of toxicity and single-dose
pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and
patients with advanced solid tumors. Expert Opin. Drug Metab. Toxicol., 9(2), 117–125.
Wang, X., Zhang, F., Yang, L., et al., (2011). Ursolic acid inhibits proliferation and induces
apoptosis of cancer cells in vitro and in vivo. J. BioMed. Biotechnol., 419343.
Wang, Y., Song, J., Chow, S. F., et al., (2015). Particle size tailoring of ursolic acid
nanosuspensions for improved anticancer activity by controlled antisolvent precipitation.
Int. J. Pharm., 494(1), 479–489.
Weng, H., Tan, Z. J., Hu, Y. P., et al., (2014). Ursolic acid induces cell cycle arrest and
apoptosis of gallbladder carcinoma cells. Cancer Cell Int., 14(96), 1–10.
World Health Organization: International Agency for Research on Cancer. Cervical
cancer estimated incidence, mortality and prevalence worldwide in 2012. World Health
Organization. 2012.
Wu, B., Wang, X., Chi, Z. F., et al., (2012). Ursolic acid-induced apoptosis in K562 cells
involving upregulation of PTEN gene expression and inactivation of the PI3K/Akt pathway.
Arch Pharm. Res., 35(3), 543–548.
Xavier, C. P. R., Lima, C. F., Pedro, D. F. N., et al., (2012). Ursolic acid induces cell death and
modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells.
J. Nutr. Biochem. [Epub ahead of print].
Xavier, C. P. R., Lima, C. F., Pedro, D. F. N., et al., (2013). Ursolic acid induces cell death and
modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells.
J. Nutr. Biochem., 24(4), 706–712.
Xie, H., Ji, Y., Tian, Q., et al., (2017). Autogenous bone particle/titanium fiber composites for
bone regeneration in a rabbit radius critical-size defect model. Connect Tissue Res., 58(6),
553–561.
Xie, J., Yang, Z. G., Zhou, C. G., et al., (2016). Nanotechnology for the delivery of
phytochemicals in cancer therapy. Biotechnol. Adv., 34(4), 343–353.
100
https://t.me/medicina_free
Yamai, H., Sawada, N., Yoshida, T., et al., (2009). Triterpenes augment the inhibitory effects
of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress
experimental metastasis in vivo. Int. J. Cancer, 125(4), 952–960.
Yan, S. L., Huang, C. Y., Wu, S. T., et al., (2010). Oleanolic acid and ursolic acid induce
apoptosis in four human liver cancer cell lines. Toxicol. In Vitro, 24(3), 842–848.
Yang, G., Yang, T., Zhang, W., et al., (2014). In vitro and in vivo antitumor effects of folate-
targeted ursolic acid stealth liposome. J. Agric. Food Chem., 62(10), 2207–2215.
Yin, M. C., Lin, M. C., Mong, M. C., et al., (2012). Bioavailability, distribution, and antioxidative
effects of selected triterpenes in mice. J. Agric. Food Chem., 60(31), 7697–7701.
Zhang, H., Li, X., Ding, J., et al., (2013). Delivery of ursolic acid (UA) in polymeric
nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced
inhibition of cyclooxygenase 2(COX-2). Int. J. Pharm., 441(1), 261–268.
Zhang, J., Zhao, S., Zhu, Y., et al., (2014). Three-dimensional printing of strontium-containing
mesoporous bioactive glass scaffolds for bone regeneration. Acta Biomater., 10(5),
2269–2281.
Zhang, Y. L., Xia, L., Zhai, D., et al., (2015). Mesoporous bioactive glass nanolayer-
functionalized 3D-printed scaffolds for accelerating osteogenesis and angiogenesis.
Nanoscale, 7(45), 19207–19221.
Zhang, Y., Kong, C., Zeng, Y., et al., (2010). Ursolic acid induces PC-3 cell apoptosis via
activation of JNK and inhibition of Akt pathways in vitro. Mol. Carcinog., 49(4), 374–385.
Zhao, T., Liu, Y., Gao, Z., et al., (2015). Self-assembly and cytotoxicity study of PEG-modified
ursolic acid liposomes. Mater. Sci. Eng., 53, 196–203.
Zheng, Q. Y., Jin, F. S., Yao, C., et al., (2012). Ursolic acid-induced AMP-activated protein
kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder
cancer T24 cells. Biochem. Biophys. Res. Commun., 419(4), 741–747.
Zheng, Q. Y., Li, P. P., Jin, F. S., et al., (2013). Ursolic acid induces ER stress response to
activate ASK1-JNK signaling and induce apoptosis in human bladder cancer T24 cells. Cell
Signal, 25(1), 206–213.
Zhou, X. J., Hu, X. M., Yi, Y. M., et al., (2009). Preparation and body distribution of freeze-
dried powder of ursolic acid phospholipid nanoparticles. Drug Dev. Ind. Pharm., 35(3),
305–310.
Zhu, Z., Qian, Z., Yan, Z., et al., (2013). A Phase I pharmacokinetic study of ursolic acid
nanoliposomes in healthy volunteers and patients with advanced solid tumors. Int. J.
Nanomed., 8, 129.
Biomarkers as Targeted Herbal Drug Discovery
CHAPTER 5
https://t.me/medicina_free
Phytoconstituent-Centered Byproducts
and Nanomedicines as Leishmanicidal
Scavengers
SABYA SACHI DAS, P. R. P. VERMA, and SANDEEP KUMAR SINGH
Department of Pharmaceutical Sciences and Technology,
ABSTRACT
Leishmaniasis is considered as clinical expression triggered by the protozoal
parasites of the genus Leishmania. Almost 1.6 million of new individual cases
cutaneous leishmaniasis (CL) and more than half a million of new individual
cases of visceral leishmaniasis (VL) ensue every year all over the world. Above
half a century, the medical manifestations of this infection have been cured
almost entirely with the pentavalent antimonial combinations. The major disadvantage in the management of leishmaniasis includes its advent of resistance
to the existing chemotherapeutics. Leishmanicidal agents need to be directed
in low doses as the usually procured drugs show severe adverse effects, and
henceforth drug resistance can occur promptly. To date, vaccination methods
and approaches have been found to be unsuccessful to arrive for clinical trials,
chemotherapy centered small molecular ailments are provisionally the exclusive curing strategy. Plants are the innocuous sources of bioactive compounds,
which have been reported to be effective primarily, chemically stable, and
least harmful as compared with the synthetic molecules. The natural products,
chiefly plant-originated phytoconstituents and their byproducts of varied structural groups and classes, displaying the anti-leishmanial activity (ALA), further
could be established for their potential efficacy in drug development systems
and biomedical research, have been reported in this review. New studies have
102
https://t.me/medicina_free
Biomarkers as Targeted Herbal Drug Discovery
been emphasized with some biopharmaceutical nano-technologies for designing
varied drug delivery approaches, including nanoparticles (NPs), nanocapsules
(NCs), liposomes, micelles, cochleate, and nanotubes. Furthermore, the current
resistance of anti-leishmanial available drugs and their lethal effects has fetched
the drift to measure the ALA of several plant-derived phytoconstituents extracts
and their refined compounds further briefed in this review.
Leishmaniasis is considered as one of the most neglected parasitic disease
chiefly caused by Leishmania (protozoan parasites) whose transmission and
spreading to human beings is assisted through the infected female phlebotomine sandflies bite. The pathology of this disease primarily takes three chief
forms: VL (kala-azar), CL, and mucocutaneous leishmaniasis (MCL) (http://
www.who.int/mediacenter/factsheets/fs375/en, accessed on 18 October, 2017).
World Health Organization (WHO) estimated that almost 1.6 million of
fresh leishmaniasis case reports ensue annually, of which half a million cases
are related to CL (almost 90% appear in countries like India, Bangladesh,
Nepal, Brazil, Sudan, and Ethiopia) and more than half a million cases are
related to VL (almost 90% occur in Algeria, Afghanistan, Saudi Arabia,
Iran, Brazil, Peru, Syria, and Sudan) (http://whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf). As per the reported data’s, Leishmaniasis presently affects an appraised of 12 million individuals and nearly 330
million individuals survive at peril of infection, while a projected count of
500 000 people dies yearly due to VL. Additionally, immunosuppressive
disorders like AIDS, add on to the advent of extreme clinical forms of this
disease. Till day, the Mediterranean basin has been reported for extreme
incidence Leishmania-HIV co-infection (
http://www.cdc.gov/parasites/
leishmaniasis/, accessed 20 August, 2013; Columba et al., 2009).
CL, conventionally termed as Delhi Boil (Ayub et al., 2003), is frequently
prevalent in tropical (humid) and subtropical sections of the world (Alrajhi,
2003). This situation of the disease is not lethal, but the defacement is a
disgrace, which primes to communal segregation, mental stress, and minor
prospects of scal afuence (Rafferty, 2005). The usually reported causative
agents for CL are L. peruviana, Leishmania (L) braziliensis, L. panamensis,
L. guyanensis, L. mexicana, L. pifanoi, L. venezuelensis, L. garnhami, L.
aethiopica, L. killicki, L. lainsoni, L. major, L. colombiensis, L. amazonensis
and L. tropica (Reithinger et al., 2007). Imperfect or no cure of CL may lead
to the subsequent expansion of MCL (Goto and Lindoso, 2010).
MCL is predominantly caused by the parasite species, L. braziliensis,
https://t.me/medicina_free
while additional species (L. amazonensis and L. guyanensis) have also been
reported (Amato et al., 2008). The contamination of mucocutaneous area by
these parasites resulted in the extent of contamination at the site of pharyngeal/oronasal mucosa and consequently conquers the soft matters (skin and
tissues) as well as cartilages of the nook, which further causes spontaneous
erosion. In disparity to CL, these abrasions do not reconcile instinctively. The
potency of self-healing of the skin lesions or abrasions primarily depends on
the immune response of the individual (Sacks et al., 2002).
If there is a state of immunity failure, the disease tends to be chronic,
with infection continuing to the reticuloendothelial system (RES), further
causing VL which is systemic and non-curative (Von Stebut and Udey,
2004). Complications caused by VL include episodic or unceasing malaise,
cachexia, splenomegaly, limbs, liver megaly, intestinal protruding, trunk
devastation, and pancytopenia (Badaro et al., 1996; Neva, 1990). Additionally, about 10% of the patients suffering from the disease, bone marrow are
also affected (Feise et al., 2010). VL is commonly caused by L. donovani,
appears in the Indian subcontinent region, Asia, and East Africa region,
while L. infantum is liable for contaminations in North Africa, Europe, and
Latin America region. Furthermore, if the treatment is not procured properly,
VL can also cause death (95% of cases reported). VL is considered lethal
because if treatment of the disease is not procured in time then the parasite
gets spread systematically (Pearson and Sousa, 1996) (Figure 5.1).
Leishmaniasis (including all forms) has been treated by traditional medications such as extracts of bark, leaves, and other plant parts because of their
substantial widespread in underdeveloped and poorest areas of the world. In
this context, an effort has been made by us to amass and review the published
and infrequent unpublished information’s of the naturally occurring phytoconstituents and their purest metabolites, which have been conventionally
used for healing leishmaniasis and associated diseases.
Primarily, Knowledge of the leishmania (protozoal parasite) life cycle could
be implicit by the numerous different phases of diverse species of the sandfly. The female sand-fly takes a blood meal of humans or terrestrial animals,
situation where they require a protein during the period of laying eggs, primes
to evolution of leishmanial parasite. The life cycle of the parasite surrogates
Соседние файлы в папке Библиотека им академика М.И. Перельмана